Member Info for ABftse

Morning. This is an easy multibagger.

If Adam joins BOD share price would double !

Thanks.

I want Adam on the board as well.

Last year someone on here said lab was going to cost "£4 million."
The actual cost is £300k to set-up plus similar annual costs.
The placing is done. Revenue expected for Q1/2 (H1) 2023 - not 2024.

From Dr Suzy Dilly, CEO, Valirx PLC:
- Laboratory set-up targeted for Q1 2023.
- First service users and incoming revenues target of Q1 or Q2 2023.
- Initial target list of potential customers and collaborators identified.

1hr long Q&A with Suzy and Ken: https://www.brrmedia.co.uk/broadcasts-embed/63989e73148ca54e512b033e/valirx-qa-webinar/?player_only=true

Shareholder Q&A Presentation:
https://www.valirx.com/sites/default/files/2022-12/Valirx%20Shareholder%20QA%20%5B13%20Dec%202022%20FINAL%5D.pdf

If you need company info- go to the company directly and ask.

Res 4 was voted against by shareholders - Board of Directors must deliver results/revenue and I think they know that.

Lots to look forward to here...

- New CRO lab service coming Q1 - lease already signed. This will bring work in-house to save costs - and then become revenue-generating. June 2022 they forecasted CRO turnover to be £20M within 5 years. Achievable!
- 201 results before June.
- Japan and Barcelona results Q1.

- Don't forget all - the Kings College London results (CLX001 - triple negative breast cancer) were good. Now we have a SPV to further develop (Cytolytix). Pre-clinical could take place in our new CRO lab.

From Suzy Dilly, CEO, Valirx PLC:
"I am delighted to announce the launch of Cytolytix to progress the development of CLX001 as we reach the preclinical development stage, following rigorous scientific assessment to move into full in-licensing. We are also pleased to be looking at expanding the use of the treatment, for not only triple negative breast cancer, but also ovarian cancer treatment.”

Source: https://www.valirx.com/news/valirx-signs-ip-license-agreement

I would like daily/weekly updates on the new CRO lab - pictures, video clips, etc. We should be celebrating this new CRO lab - it is going to be great !

60P by June is possible.

I'd prefer a 1-month window.

They probably withdrew Res 4 to save face - they were probably going to lose.
Message to Suzy and the board - start delivering results !

HeresHopin,
You are correct, apologies; also I think Adam/Nick's holding is larger.

jinky58,
The six directors own 1.1% of the company. Stella Panu (the one in on the Q&A) has no shares in the company.
Source: https://www.valirx.com/aim-rule-26
Adam and Nick own over 11%.

Vote No to Res 4 - to avoid massive dilution. Do it now, as you only have a few minutes left.

One Director has NO investment in the company (Val's website) but wants you to agree to massive share dilution. That will devalue / destroy your investment.

The company should not ask for more money when the Directors only have a tiny number of shares (e.g 0.14%) and a track record of not delivering on 201. The Thx strategy has not worked so we need proof that the new lab strategy will work before they ask for more money.

Panu - non-exec Director has NO SHARES IN THE COMPANY (according to Val's website).

But is advising us to accept massive dilution.

That is plainly wrong - we need a new board of directors.

Say NO to Res 4 - vote now (you only have a few hours to vote).

If you are voting NO to Res 4, you have until noon tomorrow. So really you should vote today.

Vote now if you are !

Don't leave it to others to vote.

I think share price would actually rise if we parted ways with Thx.

We need to see Director buying.

The Directors MUST buy shares to prove they back their own strategy. In any company in general, there is no point in having Directors/Senior Mgmt who are not invested.

The lab will increase share price when we get a contract/revenue. Once we do, I expect price to return to 30/40p area. IMO. DYOR.

At the AGM, the Directors said the lab would have annual revenue of £20M within 5 years. If that is achievable, and I'm sure it is, then the £500k raise is OK with me.

I would like to see more information on the lab service. They need to be moving faster in generating revenue. When they secure a customer (if they haven't already) then an RNS highlighting the fact the company is revenue-generating, for the first time in Val's history, will be a day to remember.

The milestone payment for Val201 was going to be $2M USD - the new lab will surpass that. No problem.

Would be good to see the Directors 'more invested'.

It has been a wild ride investing in Valirx in 2022.

This lab (contract research organisation) is what will transform this company imo. Suzy and Ken both have experience in revenue generating companies. They will be in full control of their work not having to subcontract. Plus Val will be generating revenue. They are on track. In Summer 2022 they said the new CRO would generate £20 million in 5 years.

What would happen if we get an RNS announcing a research contract (revenue) - we'll move to 60p/share imo.

Exciting times ahead! Don't miss out!

As Adam correctly pointed out:

201 (Thx) - £2m package first 1.5 yrs
Kings College - £400m milestone package

Obviously the Kings College tie-up is worth more - and progressing - hence the new lab is opening in Q1 2023.

Yes - price down to Nick's selling.
He has recently opened a large holding in another company; so he sold here imo.
Not down to fundamentals here, as we are going to be revenue-generating in Q1 2023.
Great time to buy!